The market's recent swoon begs the question: are chip-maker stocks good buys now? These criteria can help you decide. Read More
Dr. Joe Duarte has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
Inflation at the retail level is palpable, but Costco is making new highs while Walmart may be a victim of its own success. What gives? Read More
Trucking is a bellwether of not only economic growth but also inflationary pressures. Here's what the industry foretells. Read More
Real estate investment trusts are superb vehicles for generating income, but how will they be affected by the Fed's increasing hawkishness? Read More
When a company announces earnings, you should dig deeper and scrutinize management's earnings call with analysts and investors. Read More
The housing sector could receive a major tailwind if certain interrelated factors soon unfold. Here's a well-positioned play. Read More
A new name for a famous firm can be the kiss of death, or a prelude to success. Will Ethan Allen's symbol change affect its stock’s price? Read More
Texas Instruments may be a sleeper stock worth watching as its next earnings release approaches. Read More
I am recommending the purchase of United Healthcare June 16, 2017 165 Call (UNH_170616100C16500) up to $5. United is the largest health insurer in the U.S. The stock has fallen in sympathy with Molina Healthcare (NYSE: MOH) as the latter missed its Q$ earnings and announced that it is likely… Read More
- February 16, 2017
-
Download Issue
Now a value stock, this big pharma is managing its current drugs and its pipeline to perfection. Read More